Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.biopha.2019.109416
DC Field | Value | |
---|---|---|
dc.title | Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling | |
dc.contributor.author | Li, S. | |
dc.contributor.author | Yu, Y. | |
dc.contributor.author | Jin, Z. | |
dc.contributor.author | Dai, Y. | |
dc.contributor.author | Lin, H. | |
dc.contributor.author | Jiao, Z. | |
dc.contributor.author | Ma, G. | |
dc.contributor.author | Cai, W. | |
dc.contributor.author | Han, B. | |
dc.contributor.author | Xiang, X. | |
dc.date.accessioned | 2021-12-29T04:32:15Z | |
dc.date.available | 2021-12-29T04:32:15Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Li, S., Yu, Y., Jin, Z., Dai, Y., Lin, H., Jiao, Z., Ma, G., Cai, W., Han, B., Xiang, X. (2019). Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling. Biomedicine and Pharmacotherapy 119 : 109416. ScholarBank@NUS Repository. https://doi.org/10.1016/j.biopha.2019.109416 | |
dc.identifier.issn | 0753-3322 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/212264 | |
dc.description.abstract | Atorvastatin and its lactone form metabolite are reported to be associated with statin-induced myopathy (SIM) such as myalgia and life-threatening rhabdomyolysis. Though the statin-induced rhabdomyolysis is not common during statin therapy, its incidence will significantly increase due to pharmacokinetic drug-drug interactions (DDIs) with inhibitor drugs which inhibit atorvastatin's and its lactone's metabolism and hepatic uptake. Thus, the quantitative analysis of DDIs of atorvastatin and its lactone with cytochrome P450 3A4 (CYP3A4) and organic anion-transporting polypeptide (OATP) inhibitors is of great importance. This study aimed to predict pharmacokinetic DDIs possibly causing atorvastatin-induced rhabdomyolysis using Physiologically Based Pharmacokinetic (PBPK) Modelling. Firstly, we refined the PBPK models of atorvastatin and atorvastatin lactone for predicting the DDIs with CYP3A4 and OATP inhibitors. Thereafter, we predicted the exposure changes of atorvastatin and atorvastatin lactone originating from the case reports of atorvastatin-induced rhabdomyolysis using the refined models. The simulation results show that pharmacokinetic DDIs of atorvastatin and its lactone with fluconazole, palbociclib diltiazem and cyclosporine are significant. Consequently, clinicians should be aware of necessary dose adjustment of atorvastatin being used with these four inhibitor drugs. © 2019 | |
dc.publisher | Elsevier Masson SAS | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | Scopus OA2019 | |
dc.subject | Atorvastatin | |
dc.subject | Atorvastatin lactone | |
dc.subject | Drug-drug interactions | |
dc.subject | Physiologically based pharmacokinetic modeling | |
dc.subject | Rhabdomyolysis | |
dc.type | Article | |
dc.contributor.department | PHARMACY | |
dc.description.doi | 10.1016/j.biopha.2019.109416 | |
dc.description.sourcetitle | Biomedicine and Pharmacotherapy | |
dc.description.volume | 119 | |
dc.description.page | 109416 | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1016_j_biopha_2019_109416.pdf | 4.19 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License